These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 17704318)

  • 1. Stability of linear and macrocyclic gadolinium based contrast agents.
    Schmitt-Willich H
    Br J Radiol; 2007 Jul; 80(955):581-2; author reply 584-5. PubMed ID: 17704318
    [No Abstract]   [Full Text] [Related]  

  • 2. "Stability" of gadolinium chelates.
    Tweedle MF
    Br J Radiol; 2007 Jul; 80(955):583-4; author reply 584-5. PubMed ID: 17704319
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review.
    Port M; Idée JM; Medina C; Robic C; Sabatou M; Corot C
    Biometals; 2008 Aug; 21(4):469-90. PubMed ID: 18344005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The developmental history of the gadolinium chelates as intravenous contrast media for magnetic resonance.
    Runge VM; Ai T; Hao D; Hu X
    Invest Radiol; 2011 Dec; 46(12):807-16. PubMed ID: 22094366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tris(pyrone) chelates of Gd(III) as high solubility MRI-CA.
    Puerta DT; Botta M; Jocher CJ; Werner EJ; Avedano S; Raymond KN; Cohen SM
    J Am Chem Soc; 2006 Feb; 128(7):2222-3. PubMed ID: 16478170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymeric gadolinium chelate magnetic resonance imaging contrast agents: design, synthesis, and properties.
    Ladd DL; Hollister R; Peng X; Wei D; Wu G; Delecki D; Snow RA; Toner JL; Kellar K; Eck J; Desai VC; Raymond G; Kinter LB; Desser TS; Rubin DL
    Bioconjug Chem; 1999; 10(3):361-70. PubMed ID: 10346865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of thermodynamic and kinetic parameters in gadolinium chelate stability.
    Idée JM; Port M; Robic C; Medina C; Sabatou M; Corot C
    J Magn Reson Imaging; 2009 Dec; 30(6):1249-58. PubMed ID: 19938037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of molecular descriptors in the design of gadolinium (III) chelates as MRI contrast agents.
    Maiocchi A
    Mini Rev Med Chem; 2003 Dec; 3(8):845-59. PubMed ID: 14529503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular gadolinium contrast agents: differences in stability.
    Morcos SK
    Eur J Radiol; 2008 May; 66(2):175-9. PubMed ID: 18343072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GdIII complexes with fast water exchange and high thermodynamic stability: potential building blocks for high-relaxivity MRI contrast agents.
    Laus S; Ruloff R; Tóth E; Merbach AE
    Chemistry; 2003 Aug; 9(15):3555-66. PubMed ID: 12898682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New aromatic macrocyclic gadolinium chelates with enhanced relaxivity.
    Zhang X; Pillai R; Shukla R; Ranganathan RS; Tweedle M
    Invest Radiol; 1994 Jun; 29 Suppl 2():S69-70. PubMed ID: 7928275
    [No Abstract]   [Full Text] [Related]  

  • 12. High-relaxivity MRI contrast agents: where coordination chemistry meets medical imaging.
    Werner EJ; Datta A; Jocher CJ; Raymond KN
    Angew Chem Int Ed Engl; 2008; 47(45):8568-80. PubMed ID: 18825758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of novel macrocyclic and acyclic ligands as contrast enhancement agents for magnetic resonance imaging.
    Chong HS; Garmestani K; Bryant LH; Milenic DE; Overstreet T; Birch N; Le T; Brady ED; Brechbiel MW
    J Med Chem; 2006 Mar; 49(6):2055-62. PubMed ID: 16539394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C.
    Frenzel T; Lengsfeld P; Schirmer H; Hütter J; Weinmann HJ
    Invest Radiol; 2008 Dec; 43(12):817-28. PubMed ID: 19002053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Physico-chemical and toxicological profile of gadolinium chelates as contrast agents for magnetic resonance imaging].
    Idée JM; Fretellier N; Thurnher MM; Bonnemain B; Corot C
    Ann Pharm Fr; 2015 Jul; 73(4):266-76. PubMed ID: 25731664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cleavable β-cyclodextrin nanocapsules incorporating Gd(III)-chelates as bioresponsive MRI probes.
    Martinelli J; Fekete M; Tei L; Botta M
    Chem Commun (Camb); 2011 Mar; 47(11):3144-6. PubMed ID: 21270985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand design strategies to increase stability of gadolinium-based magnetic resonance imaging contrast agents.
    Clough TJ; Jiang L; Wong KL; Long NJ
    Nat Commun; 2019 Mar; 10(1):1420. PubMed ID: 30926784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fast and easy access to efficient bifunctional chelators for MRI applications.
    Gugliotta G; Botta M; Giovenzana GB; Tei L
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3442-4. PubMed ID: 19477128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action.
    Caravan P
    Acc Chem Res; 2009 Jul; 42(7):851-62. PubMed ID: 19222207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower ligand denticity leading to improved thermodynamic and kinetic stability of the Gd3+ complex: the strange case of OBETA.
    Baranyai Z; Botta M; Fekete M; Giovenzana GB; Negri R; Tei L; Platas-Iglesias C
    Chemistry; 2012 Jun; 18(25):7680-5. PubMed ID: 22615142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.